EGFR and non-small cell lung carcinoma: It is estimated to enroll 1210 stage IIA–IIIB (AJCC 8th TNM stage) participants with NSCLC without EGFR mutations or ALK rearrangements (applicable only to patients with nonsquamous tumors).